News

Ripple CTO Critiques Bitcoin's Technological Viability

Ripple CTO Critiques Bitcoin's Technological Viability

Ripple CTO Critiques the Future of Bitcoin Technology

David Schwartz, the CTO Emeritus of Ripple, made headlines with his bold statement categorizing Bitcoin (CRYPTO: BTC) as a ‘technological dead end’. In a recent discussion on X, he expressed concerns over Bitcoin’s long-term potential, particularly in the face of advancing technology.

Analyzing the 'Technological Dead End'

During an exchange with users, Schwartz was questioned about whether he would consider working on Bitcoin again after his role in creating the XRP Ledger. His reply was clear; he believes that Bitcoin lacks essential innovation. Schwartz stated, "Not really. I think Bitcoin is largely a technological dead end for the same reason the dollar is.”

Schwartz argues that Bitcoin's success does not significantly rely on blockchain technology itself. In his view, the critical aspect that keeps Bitcoin interesting is simply the expectation that it will remain usable and transferable for the foreseeable future. He elaborated, "For 99% of what makes Bitcoin interesting, all the blockchain needs to do is allow people to hold and transfer it in the future.”

However, he did recognize an exception to this view, noting that Bitcoin will ultimately require improvements to be quantum-resistant. Schwartz warned, without these upgrades, “Bitcoin will collapse,” emphasizing the potential threats to its security in an increasingly tech-savvy world.

Debating Centralization in Cryptocurrency

Schwartz's remarks about Bitcoin surfaced amidst a wider discussion regarding the inception of the XRP Ledger. Bitcoin supporter Bram Kanstein pointed out that XRP's early history appears missing, citing that it starts at block 32,570 instead of block one, implying centralization.

In response, Schwartz highlighted Bitcoin's issues with centralization, recalling significant events such as the 2010 rollback to remedy a critical bug that generated an excess of 184 billion Bitcoins. This incident revealed how Bitcoin's immutability could rely on human intervention, a fact that some critics reference when discussing its reliability.

On the other hand, regarding XRP’s development, Schwartz explained that their decision was to accept the loss of the initial ledgers rather than make coordinated changes, showcasing a different approach to decentralization within their ecosystem.

Understanding XRP's Current Market Position

Recently, XRP (CRYPTO: XRP) has been consolidating after recovering from a low near $1.15. This consolidation reflects a bullish trend, particularly noted as the Supertrend indicator at $1.2989 turned green, suggesting that buying momentum has entered the market.

As it stands, XRP's price is hovering just below the middle Bollinger Band at $1.3782, which currently represents immediate resistance. Analysts note the Supertrend at $1.2989 is crucial support, alongside secondary support levels observed between $1.20 and $1.25.

For those bullish on XRP, a successful breakthrough and sustained hold above $1.40 would signal a potential upward trend, especially if the price can clear the upper Bollinger Band at $1.4408. Resistance levels are predicted to stack up at $1.40, between $1.45 and $1.50, as well as a descending trendline reflecting peaks from previous market highs around $2.5.

In Summary: Schwartz's insights into Bitcoin's future juxtapose sharply with XRP's current market performance, potentially reshaping the conversation around cryptocurrency innovation and investment viability.

Frequently Asked Questions

What did David Schwartz say about Bitcoin?

David Schwartz called Bitcoin a 'technological dead end', arguing it lacks innovation necessary for its future success.

Why is Bitcoin considered a 'dead end'?

Schwartz suggests Bitcoin's reliance on basic transferability, rather than innovative technological features, limits its potential.

What are the current price trends for XRP?

XRP is consolidating after recovering from previous lows, and is now facing resistance just below the middle Bollinger Band.

How does Bitcoin's centralization compare to XRP's?

Schwartz argues Bitcoin has experienced significant centralization events, contrasting with XRP's decision to not make coordinated changes during its early development.

What must Bitcoin do to remain viable in the future?

Without quantum-resistant upgrades, Schwartz believes Bitcoin's future security will be jeopardized.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 11

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 17

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 15

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 14

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 11

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 14

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 12

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 8

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 9

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Logistics: eHub and Osa Commerce Strategic Alliance

Updated Category News Views 127

Revolutionizing Logistics and Fulfillment eHub and Osa Commerce have embarked on an exciting journey together, aiming to transform the logistics and fulfillment landscape. This strategic partnership focuses on enhancing the way businesses manage their supply chain and fulfillment processes, offering integrated solutions that promise efficiency and scalability. A...

Continue Reading
Investing Insights: Top Consumer Stocks to Watch Now

Updated Category News Views 227

Exploring Undervalued Consumer Stocks The consumer discretionary sector often provides unique investment opportunities, especially during periods when stocks are regarded as oversold. Monitoring key indicators like the Relative Strength Index (RSI) can help guide investors toward potential gains. Stocks with an RSI below 30 may be considered undervalued and represent...

Continue Reading
Discover the Unique Urban Sanctuary: The Standard Singapore

Updated Category News Views 234

A New Era Begins with The Standard Singapore The brand's fifth Asia Pacific property has officially welcomed guests into its urban sanctuary in the heart of the city. The Standard Singapore is poised to redefine luxury experiences, following the successful launches of The Standard, Hua Hin and The Standard, Bangkok Mahanakhon. Exceptional Accommodations This stylish...

Continue Reading
Aluminum Refractory Market to Hit $2.73B by 2031

Updated Category News Views 16

Riding the Aluminum Refractory Wave to 2031 Look, when you want to throw some cash in a market that's gaining steam, aluminum refractory materials might not be your first pick. But here's the thing: it's charging ahead to a cool $2.73 billion by 2031. And if you're keeping tabs on the likes of RHI Magnesita and Calderys, this is a sector that deserves a once-over. What...

Continue Reading
Lecomely Unveils Revolutionary AirEdge A3 Multi-Styler for All

Updated Category News Views 556

Lecomely Unveils the Innovative AirEdge A3 Multi-Styler Lecomely, a trailblazer in the beauty industry, is transforming personal care with its latest introduction, the Lecomely AirEdge A3 Multi-styler. This new styling tool is engineered to provide precision styling with a focus on maintaining hair health. Combining advanced technology and ergonomic design, it allows...

Continue Reading